Plasmid DNA and Advanced Therapies: Accelerating Path to Clinic

Webinar in collaboration with BioWin

Plasmid DNA and Advanced Therapies: Accelerating Path to Clinic


Registrations are closed

Date: December 8, 2022
Time: 14:00 CET/ 13:00 GMT/ 08:00 EST

Webinar in collaboration with BioWin

Register for the webinar


Gene therapies and emerging biomodalities are developing at an unprecedent pace, improving the lives of patients around the world. The high demand for those treatments opens a competitive market in which faster and high-quality cost-effective solutions are a clear advantage. The starting point for advanced therapies is generally DNA in the shape of plasmid DNA (pDNA). GMP requirements from early stage, together with the right tools and analytics providing the highest quality standards for pDNA, will ensure successful downstream applications as AAV, from early clinical development to commercial phase.

Join this webinar for an in-depth discussion of the challenges CGT innovators face and how experts resolve these barriers through adopting technology and strategy that drive an optimized plasmid production process and supply.

Key learning objectives

1.   Learn the current plasmid DNA manufacturing landscape.

2.   Discuss key considerations during plasmid production, including design and screening system and processing.

3.   Discuss main challenges linked to GMP pDNA production and the impact on different advanced therapy programs.


·       Nuria Gomez Santos, Ph.D,

Head of Process & Analytical Development, pDNA

·       Prof Eli Keshavarz-Moore, Professor of Bioprocess Science & Enterprise, Dept of Biochemical Engineering, Faculty of Engineering Science, UCL


 Thierry Ferain, Director Innovation & Growth, BioWin

Register Now 


Registrations are closed
Date & Time
Thursday, December 8, 2022
2:00 PM 4:00 PM (Europe/Brussels)

Add to Calendar


Zoom Webinar

--Zoom Webinar--
--Zoom Webinar--

Get the direction



+44 7825 015559

Find out what people see and say about this event, and join the conversation.


Registrations are closed